Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.56 |
| ▸ | FNTB | P49356 | 6/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445855 | 1.00 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL29445856 | 1.00 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL20558575 | 1.00 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL392068 | 1.00 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL387497 | 1.00 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL4729126 | 0.90 | LTA4H (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL4729124 | 0.90 | LTA4H (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL4739692 | 0.90 | LTA4H (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL7319165 | 0.86 | LTA4H (0.73) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL11121207 | 0.86 | LTA4H (0.73) | FNTAFNTBPGGT1BLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-02-25 | — | — | US | claimed |
| EP-3763373-A1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-01-13 | — | — | EP | claimed |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-06 | — | — | US | claimed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | claimed |
| EP-3524250-A1 | PHARMACEUTICAL COMPOSITION | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-08-14 | — | — | EP | claimed |
| WO-2018211479-A1 | STABILIZED COMPOSITIONS OF ANGIOTENSIN II INHIBITORS AND NEUTRAL ENDOPEPTIDASE INHIBITORS AND PROCESS FOR PREPARATION THEREOF | LUPIN LIMITED (IN) | 2018-11-22 | — | — | WO | claimed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | claimed |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | claimed |
| JP-4820056-B2 | — | — | 2011-11-24 | — | — | JP | claimed |
| US-20080262059-A1 | AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from hypertension | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | claimed |
| US-20080119557-A1 | A renin inhibitor, a neutral endopeptidase inhibitor, and optionally a diuretic and angiotensin II receptor blocker for the prevention or delay of a disease or condition mediated by angiotensin II and/or NEP activity; cardiovascular disorders; urogenital disorders of the kidneys; brain disorders | WEBB RANDY LEE | 2008-05-22 | — | — | US | claimed |
| EP-1863467-A2 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2007045663-A2 | COMBINATION OF AN ATI RECEPTOR ANTAGONIST AND A NP INHIBITOR FRO TREATING IA HYPERTENSION AND HEARTFAILURE | NOVARTIS AG (CH) | 2007-04-26 | — | — | WO | claimed |
| WO-2006086456-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | claimed |
| EP-1467728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | Novartis AG (CH) | 2004-10-20 | — | — | EP | claimed |
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | NOVARTIS PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | claimed |
| WO-2003059345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | NOVARTIS AG (CH) | 2003-07-24 | — | — | WO | claimed |
| WO-1992013564-A1 | COMBINATION OF AN ANGIOTENSIN II ANTAGONIST OR RENIN INHIBITOR WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR | SCHERING CORPORATION (US) | 1992-08-20 | — | — | WO | claimed |
| EP-0498361-A2 | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor | SCHERING CORPORATION (US) | 1992-08-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | MME, REN, AGTR1 | FNTA 1434/4885FNTB 2794/4885PGGT1B 2144/4885 |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, MME, ACE | FNTA 1899/4885FNTB 3550/4885PGGT1B 889/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | FNTA 1495/4885FNTB 3563/4885PGGT1B 471/4885 |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | MME, ANPEP, TMPRSS15 | FNTA 765/4885FNTB 1903/4885PGGT1B 390/4885 |
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | PREP, PEPD, FURIN | FNTA 1278/4885FNTB 2308/4885PGGT1B 520/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | FNTA 1495/4885FNTB 3563/4885PGGT1B 471/4885 |
| US-20080262059-A1 | AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from hypertension | REN, AGTR1, AGTR2 | FNTA 720/4885FNTB 2782/4885PGGT1B 1746/4885 |
| US-20080119557-A1 | A renin inhibitor, a neutral endopeptidase inhibitor, and optionally a diuretic and angiotensin II receptor blocker for the prevention or delay of a disease or condition mediated by angiotensin II and/or NEP activity; cardiovascular disorders; urogenital disorders of the kidneys; brain disorders | MME, REN, ACE | FNTA 3154/4885FNTB 3945/4885PGGT1B 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.